SBC is thrilled to announce that Aerska, a pioneering RNAi biotech focused on neurological disease, has officially launched and chosen Stevenage Bioscience Catalyst (SBC) as its UK base of lab operations.
Aerska has just disclosed US $21 million in seed financing to develop RNAi medicines targeting diseases of the brain. Their approach combines receptor-mediated “brain shuttle” delivery with RNAi chemistry to redefine the treatment of diseases such as Alzheimer’s and Parkinson’s.
“Neurological diseases remain one of the greatest challenges in medicine, with limited options to alter the course of disease,” said Jack O’Meara, CEO & Co-Founder, Aerska. “By integrating brain shuttles with RNA therapeutics, we aim to enable precise, durable gene silencing in the CNS. We’re pairing this with a strategy to match the intervention to the right patient, at the right stage of their disease.“
Headquartered in Ireland, Aerska also operates a lab base at Stevenage Bioscience Catalyst (SBC), home to science, innovation, and a thriving life-sciences community.
The Aerska team at SBC
Read more in Aerska’s news release here.
